Minimally Invasive Biopsy Techniques Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Offered (Tests, Kits & Consumables, Instruments), By Technique (Liquid Biopsy, Optical Biopsy, Brush Biopsy, Pigmented Lesion Assays, Others {Breath Biopsy etc.}), By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Extracellular Vesicles, Others {miRNA, CTECs, circRNA etc.}), By Application (Clinical and Therapeutic), By End User (Hospitals & Clinics, Ambulatory Care Center, Academic & Research Institutions), By Region, By Competition, 2020-2030F

Market Overview

The Global Minimally Invasive Biopsy Techniques Market, valued at USD 13.75 Billion in 2024, is projected to experience a CAGR of 10.30% to reach USD 24.76 Billion by 2030. Minimally invasive biopsy techniques involve diagnostic procedures designed to obtain tissue or fluid samples with reduced physical trauma, shorter recovery times, and decreased complication risks compared to conventional surgical biopsies. Key drivers propelling this market's growth include the rising global prevalence of cancer and other conditions necessitating definitive tissue diagnosis, an increasing patient inclination towards less invasive medical interventions, and continuous technological advancements in imaging guidance and device precision. These innovations enhance the accuracy and efficiency of sample collection, supporting broader clinical adoption. According to the College of American Pathologists, in 2024, a record 657 new laboratories achieved initial CAP accreditation, indicating a growing commitment to quality assurance in diagnostic pathology globally.

Despite robust growth, one significant challenge impeding market expansion is the inherent technical complexity and demanding learning curve associated with these specialized procedures, requiring substantial expertise from healthcare professionals to ensure optimal diagnostic yield and patient safety. This complexity can limit adoption rates in settings with insufficient training resources or advanced infrastructure.

Key Market Drivers

The increasing global burden of cancer and chronic diseases stands as a primary catalyst for the expansion of the minimally invasive biopsy techniques market. As diagnostic needs escalate for a growing patient population, the imperative for accurate and timely tissue sampling intensifies. These techniques offer a less intrusive yet highly effective method for obtaining critical diagnostic information, directly responding to the rising disease prevalence. According to the World Health Organization (WHO), on February 1, 2024, in "Global cancer burden growing, amidst mounting need for services," there were an estimated 20 million new cancer cases globally in 2022, underscoring the vast and continuous demand for robust diagnostic interventions. This widespread incidence drives healthcare systems to prioritize efficient and patient-friendly diagnostic pathways.

Simultaneously, advancements in imaging-guided and robotic biopsy technologies significantly propel market growth by enhancing procedural precision and safety. Innovations in visualization and automation allow clinicians to target lesions with greater accuracy, reducing the risk of complications and improving diagnostic yield. For instance, according to Quiver Quantitative, on October 8, 2025, in "Intuitive Announces FDA Clearance for AI-Enhanced Software Advancements in Ion Endoluminal System for Lung Biopsies," Intuitive received FDA clearance for AI-enhanced software advancements in its Ion endoluminal system for lung biopsies, showcasing continuous improvements in robotic-assisted diagnostic capabilities. Such technological progress broadens the applicability and adoption of minimally invasive approaches across diverse clinical settings. Reflecting broader activity within the diagnostic sector, according to Morgan Lewis, on January 25, 2024, in "Medtech and Diagnostics Market: 2023 Trends and 2024 Outlook," tools and diagnostics companies collectively raised $6.2 billion in venture capital financings across 423 deals in 2023, demonstrating substantial investment in innovative solutions.

Download Free Sample Report

Key Market Challenges

The inherent technical complexity and demanding learning curve associated with specialized minimally invasive biopsy procedures represent a significant challenge to the growth of the Global Minimally Invasive Biopsy Techniques Market. These procedures require extensive training and substantial expertise from healthcare professionals to ensure optimal diagnostic yield and patient safety. This stringent requirement limits the number of practitioners qualified to perform these advanced techniques, directly impeding broader clinical adoption.

Consequently, market expansion is hampered as healthcare facilities, especially those with insufficient training resources or advanced infrastructure, face difficulties in integrating these specialized services. The scarcity of adequately trained professionals leads to reduced procedure volumes and slower penetration of these innovative biopsy methods. According to the American College of Radiology (ACR) and the Radiology Business Management Association (RBMA) workforce survey, 69% of radiologists surveyed in 2023 reported their organization was understaffed, an increase from 67% in 2022. This persistent workforce shortage underscores the direct impact of the procedural complexity on the availability of specialists, thereby restricting the market's potential growth.

Key Market Trends

Liquid biopsy dominance and expansion represents a pivotal trend reshaping cancer diagnostics by offering minimally invasive methods for disease detection and surveillance. These blood-based tests analyze circulating tumor DNA and other biomarkers, providing a less intrusive alternative to conventional tissue biopsies, especially beneficial for inaccessible tumors or for continuous monitoring of treatment efficacy. The Association for Molecular Pathology and the College of American Pathologists collectively published 13 best practice recommendations for validating and reporting clinical circulating tumor DNA assays, indicating a growing formalization and clinical acceptance of these techniques in October 2023. This advancement facilitates earlier detection of recurrence and precise assessment of therapeutic response. For example, the SERENA-6 Phase III Trial demonstrated the clinical utility of the Guardant360 CDx test, showing a 56% better cancer detection in breast cancer treatment by identifying emergent ESR1 mutations during first-line endocrine therapy before radiological disease progression, as reported by Guardant Health in June 2025.

Artificial intelligence for diagnostic enhancement is transforming minimally invasive biopsy techniques by significantly improving the precision and efficiency of pathological analysis. AI algorithms assist in identifying subtle patterns in imaging and histological samples that might be overlooked, leading to more accurate and timely diagnoses. The American College of Radiology reported that nearly 80% of FDA-cleared medical AI algorithms are specifically developed for imaging applications, underscoring AI's widespread integration into diagnostic workflows by September 2025. This capability reduces diagnostic variability and promotes more consistent interpretation across various clinical settings. PathAI, a prominent developer in AI-powered pathology, unveiled its novel AI products, PathExplore Immuno-Oncology Profiling (IOP) and IHC Explore, in May 2024, empowering cancer drug developers and clinical researchers with AI-driven insights for detailed analysis of the tumor microenvironment. Such innovations enhance biomarker discovery and deepen the understanding of treatment response, directly influencing patient management strategies derived from biopsy results.

Segmental Insights

Within the Global Minimally Invasive Biopsy Techniques Market, Liquid Biopsy emerges as the fastest growing segment. This rapid expansion is primarily driven by its non-invasive nature, which significantly enhances patient comfort and reduces procedural risks compared to traditional tissue biopsies. Liquid biopsy facilitates real-time monitoring of disease progression and treatment efficacy through repeated sampling, providing dynamic insights into tumor heterogeneity. Its capacity for early cancer detection and guiding personalized therapeutic strategies, further supported by regulatory approvals for specific diagnostic assays from bodies like the FDA, strongly propels its increasing adoption in oncology. This approach offers a comprehensive and less burdensome diagnostic pathway, improving patient management.

Regional Insights

North America leads the Global Minimally Invasive Biopsy Techniques Market due to its highly developed healthcare infrastructure, which features state-of-the-art medical facilities and advanced imaging capabilities. The region demonstrates a high adoption rate of sophisticated diagnostic technologies, including imaging-guided and liquid biopsy solutions, enhancing procedural precision. Favorable reimbursement policies further incentivize the widespread utilization of these minimally invasive procedures, ensuring accessibility. Moreover, a supportive regulatory environment, spearheaded by bodies such as the U. S. Food and Drug Administration, facilitates rapid innovation and commercialization of new biopsy devices. This robust ecosystem, combined with a significant burden of chronic diseases, particularly cancer, drives continuous demand for advanced diagnostic methods. .

Recent Developments

• In October 2025, Intuitive announced that the U.S. Food and Drug Administration (FDA) cleared software advancements for its Ion endoluminal system. The Ion robotic-assisted bronchoscopy platform, which uses an ultra-thin, shape-sensing catheter, enables physicians to perform minimally invasive biopsies deep within the lung, accessing small, hard-to-reach nodules. The updated software integrates artificial intelligence across the navigational workflow and incorporates enhanced imaging capabilities. These improvements are designed to support more accurate and efficient lung biopsies by addressing challenges such as CT-to-body divergence, where lung nodule positions may shift during the procedure, thereby advancing minimally invasive diagnostic precision.

• In May 2025, Exact Sciences launched its Oncodetect test, a molecular residual disease and recurrence monitoring solution, following its earlier March 2025 introduction of the Cologuard Plus test. The Oncodetect test identifies residual disease earlier than current imaging standards, marking a significant advancement in non-invasive cancer monitoring. Cologuard Plus, an updated colorectal cancer screening test, features novel biomarkers and improved laboratory processes to reduce false positives while maintaining high sensitivity. These new product launches by Exact Sciences reinforce the company's portfolio of non-invasive diagnostic options, directly impacting the global minimally invasive biopsy techniques market by providing advanced screening and monitoring tools.

• In October 2024, QIAGEN expanded its automated liquid biopsy portfolio, introducing new kits and updating its EZ2 Connect platform to enhance non-invasive applications in oncology, prenatal care, and organ transplantation. This expansion reinforced the company's commitment to advancing liquid biopsy technologies, which offer a non-invasive method for detecting and monitoring disease biomarkers using biofluid samples like blood or urine. The new ccfDNA Kit upgrade includes a urine protocol, improving liquid biopsy workflows for cancer research and further strengthening QIAGEN's comprehensive solutions across various molecular detection technologies. This development directly contributes to the global minimally invasive biopsy techniques market by improving accessibility and efficiency of liquid biopsy methods.

• In October 2024, Invenio Imaging received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its NIO Lung Cancer Reveal image analysis module. This artificial intelligence (AI) tool is designed to assist physicians in the real-time evaluation of bronchoscopic lung forceps biopsies. The module identifies cell/tissue morphology suspicious for cancer in fresh biopsy specimens obtained using the NIO Laser Imaging System. This breakthrough addresses the challenge of acquiring adequate tissue for biomarker and treatment determination in minimally invasive bronchoscopic lung biopsies, particularly when rapid on-site evaluation is unavailable. The designation aims to accelerate the development and review of this innovative technology.

Key Market Players

• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• PerkinElmer Inc.
• QIAGEN NV
• Guardant Health, Inc.
• Veracyte, Inc.
• Myriad Genetics, Inc.
• Biocept, Inc.
• NeoGenomics Laboratories, Inc.
• Adaptive Biotechnologies Corporation

Report Scope:

In this report, the Global Minimally Invasive Biopsy Techniques Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Minimally Invasive Biopsy Techniques Market, By Product Offered:

o   Tests

o   Kits & Consumables

o   Instruments

• Minimally Invasive Biopsy Techniques Market, By Technique:

o   Liquid Biopsy

o   Optical Biopsy

o   Brush Biopsy

o   Pigmented Lesion Assays

o   Others

• Minimally Invasive Biopsy Techniques Market, By Circulating Biomarker:

o   Circulating Tumor Cells (CTCs)

o   Cell Free DNA (cfDNA)

o   Circulating Tumor DNA (ctDNA)

o   Extracellular Vesicles

o   Others

• Minimally Invasive Biopsy Techniques Market, By Application:

o   Clinical

o   Therapeutic

• Minimally Invasive Biopsy Techniques Market, By End User:

o   Hospitals & Clinics

o   Ambulatory Care Center

o   Academic & Research Institutions

• Minimally Invasive Biopsy Techniques Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Minimally Invasive Biopsy Techniques Market.

Available Customizations:

Global Minimally Invasive Biopsy Techniques Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Minimally Invasive Biopsy Techniques Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]